| Previous Close | 31.39 |
| Open | 31.33 |
| Bid | 31.91 x 200 |
| Ask | 31.96 x 300 |
| Day's Range | 31.03 - 32.11 |
| 52 Week Range | 20.68 - 40.83 |
| Volume | 435,941 |
| Avg. Volume | 1,531,646 |
| Market Cap | 3.9B |
| Beta | 4.51 |
| PE Ratio (TTM) | -12.24 |
| EPS (TTM) | -2.61 |
| Earnings Date | Aug 2, 2017 - Aug 7, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.89 |
- Zacks•2 hours ago
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Markit•4 hours agoSee what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of ACAD earnings conference call or presentation 8-Aug-17 9:00pm GMT
Q2 2017 ACADIA Pharmaceuticals Inc Earnings Call
